New hope for hard-to-treat blood cancers? early trial stopped short

NCT ID NCT06563804

Terminated Disease control Sponsor: Servier Bio-Innovation LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called S227928, alone or with another drug (venetoclax), in people with certain blood cancers (AML, MDS/AML, or CMML) that returned or didn't respond to prior therapy. The goal was to find a safe dose and see if it helps. The trial was terminated early after enrolling 13 participants, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia Myelodysplastic Syndromes Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) MYELODYSPLASTIC SYNDROME (MDS)/AML RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

CHU de Bordeaux - Hopital du Haut Levêque

Pessac, 33604, France
Chu de Nice - Hôpital L'archet 1

Nice, 062000, France
City of Hope

Duarte, California, 91010, United States
Fred Hutch Cancer Center

Seattle, Washington, 98109, United States
Helsinki University Hospital - Comprehensive Cancer Center

Helsinki, 00029, Finland
Institut Gustave Roussy

Villejuif, 94800, France
Institut Paoli Calmette

Marseille, 13009, France
Klinikum rechts der Isar der TU München

München, 81675, Germany
Memorial Sloan Kettering

New York, New York, 10065, United States
Peter MacCallum Cancer Centre

Melbourne, 3000, Australia
Prince of Wales Hospital

Randwick, 2031, Australia
START Midwest

Grand Rapids, Michigan, 49546, United States
Sapporo Hokuyu Hospital

Hokkaido, 003-0006, Japan
The University of Kansas

Fairway, Kansas, 66205, United States
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Tokyo, 113-8677, Japan
Universitätsklinikum Ulm

Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.